Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

BACKGROUND: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). METHODS: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 mill...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Procopio, G, Verzoni, E, Bracarda, S, Ricci, S, Sacco, C, Ridolfi, L, Porta, C, Miceli, R, Zilembo, N, Bajetta, E
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2011
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3078589/
https://ncbi.nlm.nih.gov/pubmed/21448165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.103
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars